Moderna
Search results
May 6, 2024 · Continued development and commercial preparation for a 2024 season variant-adapted COVID-19 vaccine. First quarter 2024 revenues of €187.6 million, net loss of €315.1 million and loss per share of €1.31 ($1.421) Maintained strong financial position with €16.9 billion in cash, cash equivalents and security investments.
2 days ago · MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno ...
May 6, 2024 · MAINZ, Germany, May 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months ended March 31, 2024, and provided...
May 6, 2024 · Reuters. Mon, May 6, 2024, 6:49 AM 1 min read. In this article: BNTX. PFE. FRANKFURT, May 6 (Reuters) - Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used...
May 6, 2024 · FRANKFURT, May 6 (Reuters) - Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024...
May 3, 2024 · BioNTech delivered its first mRNA vaccines to people with treatment-resistant melanoma nearly a decade ago. But when the pandemic hit, development of mRNA vaccines jumped into warp drive. Now...
May 7, 2024 · News for BioNTech. Strong Financials and Promising Oncology Pipeline Support Buy Rating for BioNTech SE. TipRanks. May. 7, 2024, 05:51 AM. Analyst William Maughan of Canaccord Genuity...
